Q3198939 (Q3198939): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): CEREBROVASCULAR DISEASES ARE ONE OF THE MAIN CAUSES OF DEATH AND LONG-TERM DISABILITY IN ADULTS. THERE ARE CURRENTLY NO EFFECTIVE THERAPIES TO REPAIR DAMAGED BRAIN REGIONS AFTER AN INJURY. ONE OF THE MOST PROMISING STRATEGIES IN NEURORESTAURATION IS BASED ON CELL THERAPY WITH MOTHER CELLS AND PARENTS OF MESENCHYMAL ORIGIN (MSC). THE NEUROTROFICAS AND IMMUNOMODULATORY CHARACTERISTICS OF MSC CONTRIBUTE TO THEIR THERAPEUTIC EFFECTS. ALTHOUGH THE VI...) |
||||||||||||||
| Property / summary | |||||||||||||||
CEREBROVASCULAR DISEASES ARE ONE OF THE MAIN CAUSES OF DEATH AND LONG-TERM DISABILITY IN ADULTS. THERE ARE CURRENTLY NO EFFECTIVE THERAPIES TO REPAIR DAMAGED BRAIN REGIONS AFTER AN INJURY. ONE OF THE MOST PROMISING STRATEGIES IN NEURORESTAURATION IS BASED ON CELL THERAPY WITH MOTHER CELLS AND PARENTS OF MESENCHYMAL ORIGIN (MSC). THE NEUROTROFICAS AND IMMUNOMODULATORY CHARACTERISTICS OF MSC CONTRIBUTE TO THEIR THERAPEUTIC EFFECTS. ALTHOUGH THE VIABILITY, SAFETY AND TOLERANCE OF MSC TRANSPLANTATION ARE BEING EXAMINED IN PRECLINIC AND CLINICAL TRIALS WITH ACCEPTABLE RESULTS, THE TRANSPLANTATION OF MSC IN MODELS OF BRAIN DAMAGE IS QUITE INEFFECTIVE AND THE FUNCTIONAL RESPONSE IS SCARCE. THE LACK OF EFFICACY IS RELATED TO A PROBLEM OF RETENTION AND SURVIVAL OF CSM IN THE GRAFT AREA. IN THIS PROJECT WE HYPOTHESISED THAT THE INTRACEREBRAL INJECTION OF MSC ENCAPSULATED IN A HYDROGEL OF IN SITU FORMATION MADE FROM FIBROIN OF THE SILK BIOFUNCIONALISED (BSF) COULD SIGNIFICANTLY PROMOTE RETENTION AND LONG-TERM SURVIVAL OF TRANSPLANTED MSCS, INCREASING FUNCTIONAL RECOVERY AFTER BRAIN DAMAGE. IN THIS CONTEXT, IT IS NECESSARY TO OBTAIN INFORMATION ON THE BIOCOMPATIBILITY OF BSF HYDROGELS TO ENCAPSULATE MSCS WHILE PRESERVING THEIR NEUROTROFICAS FUNCTIONALITIES AND TO EXAMINE THE SAFETY AND TOLERANCE OF THIS BIOMATERIAL IMPLANTED IN BRAIN TISSUE. THE OBJECTIVES OF THIS PROPOSAL ARE TO: OBTAIN AND CHARACTERISE A BSF CONJUGATED WITH BIOACTIVE PEPTIDES TO DEVELOP AN INJECTABLE SYSTEM BASED ON A HYDROGEL STRUCTURE; II) TO STUDY IN VITRO THE INTERACTION AND FUNCTION OF BSF HYDROGELS AND TO EVALUATE IN VIVO BSF BIORESPONSES AND BRAIN FUNCTION OF ANIMALS IMPLANTED INTRACEREBRALLY WITH THIS BIOMATERIAL. THE CLINICAL PROJECTION OF THIS STRATEGY IS SUPPORTED BY THE FACT THAT SILK FIBROIN HAS BEEN USED FOR YEARS IN A WIDE VARIETY OF BIOMEDICAL APPLICATIONS. THE GENERAL OBJECTIVE OF THIS PROJECT IS TO IDENTIFY AND EXPLOIT A NEW APPROACH BASED ON THE USE OF BSF BIOHIBRIDOS TO PROMOTE REPAIR AND FUNCTIONAL RECOVERY, HAVING AN IMPACT ON THE DEVELOPMENT OF EXPERIMENTAL STRATEGIES FOR REPAIRING BRAIN DAMAGE AND DEGENERATION (English) | |||||||||||||||
| Property / summary: CEREBROVASCULAR DISEASES ARE ONE OF THE MAIN CAUSES OF DEATH AND LONG-TERM DISABILITY IN ADULTS. THERE ARE CURRENTLY NO EFFECTIVE THERAPIES TO REPAIR DAMAGED BRAIN REGIONS AFTER AN INJURY. ONE OF THE MOST PROMISING STRATEGIES IN NEURORESTAURATION IS BASED ON CELL THERAPY WITH MOTHER CELLS AND PARENTS OF MESENCHYMAL ORIGIN (MSC). THE NEUROTROFICAS AND IMMUNOMODULATORY CHARACTERISTICS OF MSC CONTRIBUTE TO THEIR THERAPEUTIC EFFECTS. ALTHOUGH THE VIABILITY, SAFETY AND TOLERANCE OF MSC TRANSPLANTATION ARE BEING EXAMINED IN PRECLINIC AND CLINICAL TRIALS WITH ACCEPTABLE RESULTS, THE TRANSPLANTATION OF MSC IN MODELS OF BRAIN DAMAGE IS QUITE INEFFECTIVE AND THE FUNCTIONAL RESPONSE IS SCARCE. THE LACK OF EFFICACY IS RELATED TO A PROBLEM OF RETENTION AND SURVIVAL OF CSM IN THE GRAFT AREA. IN THIS PROJECT WE HYPOTHESISED THAT THE INTRACEREBRAL INJECTION OF MSC ENCAPSULATED IN A HYDROGEL OF IN SITU FORMATION MADE FROM FIBROIN OF THE SILK BIOFUNCIONALISED (BSF) COULD SIGNIFICANTLY PROMOTE RETENTION AND LONG-TERM SURVIVAL OF TRANSPLANTED MSCS, INCREASING FUNCTIONAL RECOVERY AFTER BRAIN DAMAGE. IN THIS CONTEXT, IT IS NECESSARY TO OBTAIN INFORMATION ON THE BIOCOMPATIBILITY OF BSF HYDROGELS TO ENCAPSULATE MSCS WHILE PRESERVING THEIR NEUROTROFICAS FUNCTIONALITIES AND TO EXAMINE THE SAFETY AND TOLERANCE OF THIS BIOMATERIAL IMPLANTED IN BRAIN TISSUE. THE OBJECTIVES OF THIS PROPOSAL ARE TO: OBTAIN AND CHARACTERISE A BSF CONJUGATED WITH BIOACTIVE PEPTIDES TO DEVELOP AN INJECTABLE SYSTEM BASED ON A HYDROGEL STRUCTURE; II) TO STUDY IN VITRO THE INTERACTION AND FUNCTION OF BSF HYDROGELS AND TO EVALUATE IN VIVO BSF BIORESPONSES AND BRAIN FUNCTION OF ANIMALS IMPLANTED INTRACEREBRALLY WITH THIS BIOMATERIAL. THE CLINICAL PROJECTION OF THIS STRATEGY IS SUPPORTED BY THE FACT THAT SILK FIBROIN HAS BEEN USED FOR YEARS IN A WIDE VARIETY OF BIOMEDICAL APPLICATIONS. THE GENERAL OBJECTIVE OF THIS PROJECT IS TO IDENTIFY AND EXPLOIT A NEW APPROACH BASED ON THE USE OF BSF BIOHIBRIDOS TO PROMOTE REPAIR AND FUNCTIONAL RECOVERY, HAVING AN IMPACT ON THE DEVELOPMENT OF EXPERIMENTAL STRATEGIES FOR REPAIRING BRAIN DAMAGE AND DEGENERATION (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: CEREBROVASCULAR DISEASES ARE ONE OF THE MAIN CAUSES OF DEATH AND LONG-TERM DISABILITY IN ADULTS. THERE ARE CURRENTLY NO EFFECTIVE THERAPIES TO REPAIR DAMAGED BRAIN REGIONS AFTER AN INJURY. ONE OF THE MOST PROMISING STRATEGIES IN NEURORESTAURATION IS BASED ON CELL THERAPY WITH MOTHER CELLS AND PARENTS OF MESENCHYMAL ORIGIN (MSC). THE NEUROTROFICAS AND IMMUNOMODULATORY CHARACTERISTICS OF MSC CONTRIBUTE TO THEIR THERAPEUTIC EFFECTS. ALTHOUGH THE VIABILITY, SAFETY AND TOLERANCE OF MSC TRANSPLANTATION ARE BEING EXAMINED IN PRECLINIC AND CLINICAL TRIALS WITH ACCEPTABLE RESULTS, THE TRANSPLANTATION OF MSC IN MODELS OF BRAIN DAMAGE IS QUITE INEFFECTIVE AND THE FUNCTIONAL RESPONSE IS SCARCE. THE LACK OF EFFICACY IS RELATED TO A PROBLEM OF RETENTION AND SURVIVAL OF CSM IN THE GRAFT AREA. IN THIS PROJECT WE HYPOTHESISED THAT THE INTRACEREBRAL INJECTION OF MSC ENCAPSULATED IN A HYDROGEL OF IN SITU FORMATION MADE FROM FIBROIN OF THE SILK BIOFUNCIONALISED (BSF) COULD SIGNIFICANTLY PROMOTE RETENTION AND LONG-TERM SURVIVAL OF TRANSPLANTED MSCS, INCREASING FUNCTIONAL RECOVERY AFTER BRAIN DAMAGE. IN THIS CONTEXT, IT IS NECESSARY TO OBTAIN INFORMATION ON THE BIOCOMPATIBILITY OF BSF HYDROGELS TO ENCAPSULATE MSCS WHILE PRESERVING THEIR NEUROTROFICAS FUNCTIONALITIES AND TO EXAMINE THE SAFETY AND TOLERANCE OF THIS BIOMATERIAL IMPLANTED IN BRAIN TISSUE. THE OBJECTIVES OF THIS PROPOSAL ARE TO: OBTAIN AND CHARACTERISE A BSF CONJUGATED WITH BIOACTIVE PEPTIDES TO DEVELOP AN INJECTABLE SYSTEM BASED ON A HYDROGEL STRUCTURE; II) TO STUDY IN VITRO THE INTERACTION AND FUNCTION OF BSF HYDROGELS AND TO EVALUATE IN VIVO BSF BIORESPONSES AND BRAIN FUNCTION OF ANIMALS IMPLANTED INTRACEREBRALLY WITH THIS BIOMATERIAL. THE CLINICAL PROJECTION OF THIS STRATEGY IS SUPPORTED BY THE FACT THAT SILK FIBROIN HAS BEEN USED FOR YEARS IN A WIDE VARIETY OF BIOMEDICAL APPLICATIONS. THE GENERAL OBJECTIVE OF THIS PROJECT IS TO IDENTIFY AND EXPLOIT A NEW APPROACH BASED ON THE USE OF BSF BIOHIBRIDOS TO PROMOTE REPAIR AND FUNCTIONAL RECOVERY, HAVING AN IMPACT ON THE DEVELOPMENT OF EXPERIMENTAL STRATEGIES FOR REPAIRING BRAIN DAMAGE AND DEGENERATION (English) / qualifier | |||||||||||||||
point in time: 14 October 2021
| |||||||||||||||
Revision as of 08:05, 14 October 2021
Project Q3198939 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3198939 in Spain |
Statements
105,875.0 Euro
0 references
211,750.0 Euro
0 references
50.0 percent
0 references
30 December 2016
0 references
29 December 2019
0 references
UNIVERSIDAD POLITECNICA DE MADRID
0 references
40°25'0.12"N, 3°42'12.89"W
0 references
28079
0 references
LAS ENFERMEDADES CEREBROVASCULARES CONSTITUYEN UNA DE LAS PRINCIPALES CAUSAS DE MUERTE Y DISCAPACIDAD A LARGO PLAZO EN EL ADULTO. EN LA ACTUALIDAD NO EXISTEN TERAPIAS EFICACES PARA REPARAR LAS REGIONES CEREBRALES DAÑADAS TRAS UNA LESION. UNA DE LAS ESTRATEGIAS MAS PROMETEDORAS EN NEURORESTAURACION SE BASA EN LA TERAPIA CELULAR CON CELULAS MADRE Y PROGENITORES DE ORIGEN MESENQUIMAL (MSC). LAS CARACTERISTICAS NEUROTROFICAS E INMUNOMODULADORAS DE LAS MSC CONTRIBUYEN A SUS EFECTOS TERAPEUTICOS. A PESAR DE QUE LA VIABILIDAD, SEGURIDAD Y TOLERANCIA DEL TRASPLANTE DE MSC SE ESTAN EXAMINANDO EN ENSAYOS PRECLINICOS Y CLINICOS CON RESULTADOS ACEPTABLES, EL TRANSPLANTE DE MSC EN MODELOS DE DAÑO CEREBRAL ES BASTANTE INEFICAZ Y LA RESPUESTA FUNCIONAL ESCASA. LA FALTA DE EFICACIA ESTA RELACIONADA CON UN PROBLEMA DE RETENCION Y SUPERVIVENCIA DE LAS MSC EN LA ZONA DEL INJERTO. EN ESTE PROYECTO HIPOTETIZAMOS QUE LA INYECCION INTRACEREBRAL DE MSC ENCAPSULADAS EN UN HIDROGEL DE FORMACION IN SITU FABRICADO A PARTIR DE FIBROINA DE LA SEDA BIOFUNCIONALIZADA (BSF) PODRIA FAVORECER SIGNIFICATIVAMENTE LA RETENCION Y SUPERVIVENCIA A LARGO-PLAZO DE LAS MSC TRANSPLANTADAS, INCREMENTANDO LA RECUPERACION FUNCIONAL TRAS EL DAÑO CEREBRAL. EN ESTE CONTEXTO RESULTA NECESARIO OBTENER INFORMACION SOBRE LA BIOCOMPATIBILIDAD DE LOS HIDROGELES DE BSF PARA ENCAPSULAR LAS MSC PRESERVANDO SUS FUNCIONALES NEUROTROFICAS ASI COMO EXAMINAR LA SEGURIDAD Y TOLERANCIA DE ESTE BIOMATERIAL IMPLANTADO EN EL TEJIDO CEREBRAL. LOS OBJETIVOS DE ESTA PROPUESTA SON: I) OBTENER Y CARACTERIZAR UNA BSF CONJUGADA CON PEPTIDOS BIOACTIVOS PARA DESARROLLAR UN SISTEMA INYECTABLE BASADO EN UNA ESTRUCTURA DE HIDROGEL; II) ESTUDIAR IN VITRO LA INTERACCION Y LA FUNCION DE LAS MSC ENCASULADAS EN LOS HIDROGELES DE BSF ASI COMO EVALUAR IN VIVO LAS BIORESPUESTAS Y LA FUNCION CEREBRAL DE ANIMALES IMPLANTADOS INTRACEREBRALMENTE CON ESTE BIOMATERIAL. LA PROYECCION CLINICA DE ESTA ESTRATEGIA ESTA AVALADA POR EL HECHO DE QUE LA FIBROINA DE LA SEDA SE HA UTILIZADO DURANTE AÑOS EN UNA GRAN VARIEDAD DE APLICACIONES BIOMEDICAS. EL OBJETIVO GENERAL DE ESTE PROYECTO ES IDENTIFICAR Y EXPLOTAR UN NUEVO ENFOQUE BASADO EN EL USO DE BIOHIBRIDOS DE BSF PARA PROMOVER LA REPARACION Y LA RECUPERACION FUNCIONAL, TENIENDO REPERCUSION EN EL DESARROLLO DE ESTRATEGIAS EXPERIMENTALES PARA REPARACION DEL DAÑO Y LA DEGENERACION CEREBRAL (Spanish)
0 references
CEREBROVASCULAR DISEASES ARE ONE OF THE MAIN CAUSES OF DEATH AND LONG-TERM DISABILITY IN ADULTS. THERE ARE CURRENTLY NO EFFECTIVE THERAPIES TO REPAIR DAMAGED BRAIN REGIONS AFTER AN INJURY. ONE OF THE MOST PROMISING STRATEGIES IN NEURORESTAURATION IS BASED ON CELL THERAPY WITH MOTHER CELLS AND PARENTS OF MESENCHYMAL ORIGIN (MSC). THE NEUROTROFICAS AND IMMUNOMODULATORY CHARACTERISTICS OF MSC CONTRIBUTE TO THEIR THERAPEUTIC EFFECTS. ALTHOUGH THE VIABILITY, SAFETY AND TOLERANCE OF MSC TRANSPLANTATION ARE BEING EXAMINED IN PRECLINIC AND CLINICAL TRIALS WITH ACCEPTABLE RESULTS, THE TRANSPLANTATION OF MSC IN MODELS OF BRAIN DAMAGE IS QUITE INEFFECTIVE AND THE FUNCTIONAL RESPONSE IS SCARCE. THE LACK OF EFFICACY IS RELATED TO A PROBLEM OF RETENTION AND SURVIVAL OF CSM IN THE GRAFT AREA. IN THIS PROJECT WE HYPOTHESISED THAT THE INTRACEREBRAL INJECTION OF MSC ENCAPSULATED IN A HYDROGEL OF IN SITU FORMATION MADE FROM FIBROIN OF THE SILK BIOFUNCIONALISED (BSF) COULD SIGNIFICANTLY PROMOTE RETENTION AND LONG-TERM SURVIVAL OF TRANSPLANTED MSCS, INCREASING FUNCTIONAL RECOVERY AFTER BRAIN DAMAGE. IN THIS CONTEXT, IT IS NECESSARY TO OBTAIN INFORMATION ON THE BIOCOMPATIBILITY OF BSF HYDROGELS TO ENCAPSULATE MSCS WHILE PRESERVING THEIR NEUROTROFICAS FUNCTIONALITIES AND TO EXAMINE THE SAFETY AND TOLERANCE OF THIS BIOMATERIAL IMPLANTED IN BRAIN TISSUE. THE OBJECTIVES OF THIS PROPOSAL ARE TO: OBTAIN AND CHARACTERISE A BSF CONJUGATED WITH BIOACTIVE PEPTIDES TO DEVELOP AN INJECTABLE SYSTEM BASED ON A HYDROGEL STRUCTURE; II) TO STUDY IN VITRO THE INTERACTION AND FUNCTION OF BSF HYDROGELS AND TO EVALUATE IN VIVO BSF BIORESPONSES AND BRAIN FUNCTION OF ANIMALS IMPLANTED INTRACEREBRALLY WITH THIS BIOMATERIAL. THE CLINICAL PROJECTION OF THIS STRATEGY IS SUPPORTED BY THE FACT THAT SILK FIBROIN HAS BEEN USED FOR YEARS IN A WIDE VARIETY OF BIOMEDICAL APPLICATIONS. THE GENERAL OBJECTIVE OF THIS PROJECT IS TO IDENTIFY AND EXPLOIT A NEW APPROACH BASED ON THE USE OF BSF BIOHIBRIDOS TO PROMOTE REPAIR AND FUNCTIONAL RECOVERY, HAVING AN IMPACT ON THE DEVELOPMENT OF EXPERIMENTAL STRATEGIES FOR REPAIRING BRAIN DAMAGE AND DEGENERATION (English)
14 October 2021
0 references
Madrid
0 references
Identifiers
MAT2016-79832-R
0 references